Trade Exagen Inc. - XGN CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.0418
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$1.08)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.03)Trade size with leverage ~ $5,000.00Money from leverage ~$4,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$1.08)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.03)

Key Stats

• Prev. Close: 4.6591
• Open: 4.6391
• 1-Year Change: -46.38%
• Day's Range: 4.3791 - 4.6391

Trade Exagen Inc. - XGN

About Exagen Inc

Exagen Inc. is a commercial-stage life sciences company. The Company offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The Company develops and commercialize testing products under the brand name AVISE. The Company's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases ( CTD) and Systemic lupus erythematosus (SLE). Its other diagnostic testing includes AVISE Lupus and AVISE antiphospholipid syndrome (APS). Its Prognosis tests include AVISE systemic lupus erythematosus (SLE) Prognostic, AVISE Anti- carbamylated proteins (CarP) and AVISE Platelet-bound C4d (PC4d). Its monitoring tests include AVISE SLE Monitor, AVISE methotrexate (MTX) and AVISE hydroxychloroquine (HCQ).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Exagen Inc revenues increased 22% to $35.6M. Net loss increased 50% to $19.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, general & administrative exp increase from $200K to $28.5M (expense), Other income / (expense), net decrease of 100% to $1K (income).